Salbutamol dry-powder inhalation - Acerus Pharmaceuticals

Drug Profile

Salbutamol dry-powder inhalation - Acerus Pharmaceuticals

Alternative Names: Albuterol dry-powder inhalation - Acerus Pharmaceuticals; Albuterol sulfate; Albuterol sulfate DPI; Albuterol sulfate DPI - Acerus Pharmaceuticals; Albuterol sulfate dry-powder inhalation - Acerus Pharmaceuticals; TBS-7

Latest Information Update: 26 Jan 2016

Price : $50

At a glance

  • Originator Trimel Biopharma
  • Developer Acerus Pharmaceuticals Corporation
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules; Tocolytics
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Asthma

Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 08 Sep 2015 Trimel Pharmaceuticals is now called Acerus Pharmaceuticals
  • 04 Mar 2015 Phase I development is ongoing in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top